DB16790InvestigationalGene Therapies
Devafidugene civaparvovec is an investigational in vivo genome editing product. It uses proprietary zinc finger nucleases (ZFN) that insert a functional copy of the alpha-L-iduronidase (IDUA) enzyme. Developed by Sangamo... Developed by Sangamo Therapeutics, Inc., devafidugene civaparvovec is being investigated for the treatment of mucopolysaccharidosis Type I (MPS I).
- Code names
- SB-318
Resolves to
Compound
What you can answer from here — as of April 23, 2025
Which companies are running trials of Devafidugene civaparvovec, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account